Conflict Brews In Obesity Gene Research

21 April 1996

The groups working on the two much-publicized "obesity" genes, ob and tub (tubby), look set to get embroiled in dispute over the rights to the work.

The latest twist came with the publication, in the journals Cell and Nature, of the discovery of the tub gene in mice. Sequana Therapeutics, in collaboration with researchers at the Jackson Laboratory in Maine, USA, published "a candidate gene for the mouse mutation, tubby," in the April 11 issue of Nature. Meantime, the April 19 issue of Cell carries an article by researchers at Millenium Pharmaceuticals entitled "identification and characterization of the mouse obesity gene, tubby: a member of a novel gene family."

The Nature article notes that in contrast to the rapid juvenile-onset weight gain seen in diabetic (db) and obese (ob) mice, obesity in tubby mice develops gradually, and "strongly resembles the late-onset obesity seen in the human population." This weight gain is out of proportion to their food intake (which remains normal) throughout their lives, and results in a twofold increase in body mass.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight